Diabetes

A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) glycemic measure.

Many US patients with diabetes cannot afford their medical care. The authors review the impact of interventions that reduced and/or eliminated diabetes-related costs.

A small expert panel was selected to share professional experiences with risk-sharing agreements and advance the cost-effective utilization of continuous glucose monitoring–centered care in type 2 diabetes (T2D).

The 7-mg and 14-mg oral semaglutide tablets are now indicated to reduce the risk of major adverse cardiovascular events in adults with diabetes.

Adults with diabetes were 24% less likely to visit an emergency department in 2021 than in 2019.

A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial disparities and high costs.

A CCS report found that pharmacists lack time for diabetes education as workloads rise, worsening disparities and threatening adherence.

This study describes the current opportunities and obstacles associated with Medicare Diabetes Prevention Program implementation from the novel perspective of program suppliers across the US.

A RAND report shows Medicare’s 3-year insulin savings model cut costs, improved access for beneficiaries, and offers lessons for future drug pricing reforms.

High discontinuation rates of semaglutide among older adults with diabetes reveal challenges in long-term adherence and highlight the need for improved support strategies.

A Japanese study links external eating patterns to weight loss and glycemic improvements with glucagon-like peptide-1 receptor agonists.

Data reveal a growing burden of early-onset type 2 diabetes, highlighting disparities and increased cardiometabolic risk

Daily potato consumption may improve body composition and vascular health without worsening blood sugar in adults with type 2 diabetes.

A study finds stronger CV protection from glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with higher BMI, with kidney benefits consistent across all groups.

Weekly mobile messages improved blood sugar, blood pressure, and heart health risk management in patients with type 2 diabetes (T2D), a study finds.

A study of children with type 1 diabetes (T1D) reveals major disparities in access to insulin and modern technologies, with significant impacts on glycemic control.

A review of 59 studies finds inconsistent knowledge, attitudes, and practices among health care professionals in detecting diabetic retinopathy.

Rising metabolic score for insulin resistance (METS-IR) levels strongly correlate with major cardiovascular events (MACE) and mortality in patients with type 2 diabetes (T2D), according to one study.

There is a low but increased risk of optic nerve disorders in patients with type 2 diabetes prescribed semaglutide or tirzepatide, according to a large cohort study.

A national study finds technology use and blood sugar control are up in youths and adults with type 1 diabetes, yet racial, ethnic, and socioeconomic gaps persist.

Adults with type 2 diabetes, especially those in vulnerable groups, face higher risks of medical debt, low credit scores, and bankruptcy.

Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.

Proper placement, device understanding, and ongoing support are key to helping children and adolescents with diabetes benefit from continuous glucose monitors (CGMs), explained Marry Vuong, PharmD, BCPPS, of Perfecting Peds.

Elevated levels of per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals,” may be associated with metabolic disruptions potentially leading to type 2 diabetes.

No increased risk of thrombotic events identified despite rise in erythrocytosis among sodium-glucose cotransporter 2 inhibitor (SGLT2i) users with type 2 diabetes, study finds.